dihydroergotamine has been researched along with Migraine Disorders in 280 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 75 (26.79) | 18.7374 |
| 1990's | 84 (30.00) | 18.2507 |
| 2000's | 56 (20.00) | 29.6817 |
| 2010's | 51 (18.21) | 24.3611 |
| 2020's | 14 (5.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gommeren, W; Haegeman, G; Heylen, L; Lesage, AS; Leysen, JE; Luyten, WH; Schotte, A; Van de Weyer, I; Van Gompel, P; Vanhoenacker, P; Wouters, R | 1 |
| Albrecht, D; Bérard, A; Kori, S; Strom, S; Zhao, JP | 1 |
| Aurora, SK; Cooper, W; Davies, G; Fuller, C; Hoekman, J; Ray, S; Shrewsbury, SB | 1 |
| Calabrò, RS; Casella, C; Militi, D; Raciti, G; Raciti, L | 1 |
| Ailani, J; Aurora, SK; Hirman, J; Ray, S; Shrewsbury, SB; Tepper, SJ | 1 |
| Chikkannaiah, M; Fonseca, LD; Goenka, A; Kumar, G | 1 |
| Coric, V; Harris, L; L'Italien, G; Martin, T; Moren, JA; O'Connell, T; Woolley, JJ | 1 |
| Aurora, SK; Mallick-Searle, T; Shrewsbury, SB; Starling, AJ | 1 |
| Bickel, J; Boorigie, M; Connelly, M; Sekhon, S; Stephens, D | 1 |
| Abdou, EM | 1 |
| Hoekman, J; Shrewsbury, SB; Silberstein, SD | 1 |
| Hershey, AD; Kabbouche, M; Maconochie, I; Murphy, B; Qaiser, S; Werner, K | 1 |
| Cappa, R; Goodkin, HP; Mallawaarachchi, I; Mendoza, A; Samanta, D; Theroux, LM | 1 |
| Greene, KA | 1 |
| Freitag, FG | 1 |
| Banga, AK; Eangoor, P; Joyce, JC; Knaack, JS; Nguyen, HX; Prausnitz, MR; Tas, C | 1 |
| Patterson-Gentile, C; Szperka, CL | 1 |
| Cook, CL; Shedd, GC | 1 |
| Arslan, A; Esim, O; Kurbanoglu, S; Ozkan, CK; Ozkan, SA; Ozkan, Y; Savaser, A; Tas, C | 1 |
| Evans, RW; Saper, JR | 1 |
| Tfelt-Hansen, PC | 1 |
| Lanteri-Minet, M | 1 |
| Kori, SH; Silberstein, SD | 1 |
| Chelimsky, G; Chelimsky, T; Raina, M | 1 |
| Chow, SC; Douglas, PS; Kellerman, DJ; Kori, S; Mangum, B; Noveck, RJ | 1 |
| Tepper, SJ | 1 |
| Gupta, S; Oosthuizen, R; Pulfrey, S | 1 |
| Tfelt-Hansen, P | 3 |
| Diener, HC; Tfelt-Hansen, PC | 1 |
| Becker, WJ | 2 |
| Gerard, JM; Kaar, CR; Nakanishi, AK | 1 |
| Evans, RW; Jankovic, J; Wijemanne, S | 1 |
| Danesh, A; Grothusen, J; Pourrezaei, K; Pourshoghi, A; Tabby, DS | 1 |
| Charles, A | 1 |
| Eller, M; Gelfand, AA; Goadsby, PJ; Riggins, NY; Schankin, C; Shiboski, S | 1 |
| Billinghurst, L; Crumley, ET; Durec, T; Hartling, L; Klassen, TP; Linsdell, MA; Richer, L; Russell, K; Vandermeer, B | 1 |
| Blecha, J; Chou, DE; Eller, M; Goadsby, PJ; Hawkins, RA; Kori, S; Maniyar, FH; Murphy, ST; Schankin, CJ; Seo, Y; Sprenger, T; VanBrocklin, HF | 1 |
| Chua, AL; Silberstein, S | 1 |
| Bekan, G; Tfelt-Hansen, P | 1 |
| Chou, DE; Goadsby, PJ; Tso, AR | 1 |
| Meckler, GD; Sheridan, DC | 1 |
| Cowan, RP; DeSouza, DD; O'Hare, M; Woldeamanuel, YW | 1 |
| Goadsby, PJ; Ito, H; Robbins, NM; Scheinman, MM | 1 |
| Kori, SH; Miller, SD; Pedinoff, A; Shrewsbury, SB; Weinstein, S | 1 |
| Diener, HC; Schürks, M | 2 |
| Friedman, BW; Friedman, MS; Hochberg, ML; Kapoor, A; Rowe, BH | 1 |
| Biederman, S; Burdine, D; Hershey, AD; Kabbouche, MA; LeCates, S; Manning, P; Powers, SW; Segers, A; Vaughan, P | 1 |
| Aurora, SK; Kori, SH; Rozen, TD; Shrewsbury, SB | 1 |
| Schürks, M | 1 |
| Autret-Leca, E; Beau-Salinas, F; Bensouda-Grimaldi, L; Cissoko, H; Jonville-Béra, AP | 1 |
| Charles, JA; von Dohln, P | 1 |
| FRIEDMAN, MD; WILSON, EJ | 1 |
| POLLOCK, LA | 2 |
| BLUMENTHAL, LS; FAKLER, B | 1 |
| Taylor, FR | 1 |
| Silberstein, SD | 2 |
| Lovell, BV; Marmura, MJ | 1 |
| Durham, PL; Masterson, CG | 1 |
| DANNENBERG, T | 1 |
| GOTTHELF, EJ | 1 |
| FRIEDMAN, DA; FRIEDMAN, MD | 1 |
| Galvez-Jimenez, N; Morren, JA | 1 |
| Aurora, SK; Borland, SW; Dodick, DW; Kori, SH; Silberstein, SD; Tepper, SJ; Wang, M | 1 |
| Rothrock, JF | 2 |
| Callison, CR; Kumar, AB; Miller, M | 1 |
| Cutrer, FM; Goadsby, PJ; Kori, SH; Silberstein, SD; Tepper, SJ; Wang, MH; Winner, PK | 1 |
| Bhola, R; Gandhi, S; Goadsby, PJ; Nagy, AJ | 1 |
| Borland, SW; Hu, B; Kori, SH; Mathew, NT; Silberstein, SD; Tepper, SJ; Wang, MH | 1 |
| Chang, J; Dodick, D; Febbraro, S; Forst, A; Kellerman, D; Kori, S; Taylor, G; Thomas, T; Wutann, L | 1 |
| Kelley, NE; Tepper, DE | 1 |
| Derry, CJ; Derry, S; Moore, RA | 1 |
| Peatfield, R | 1 |
| Dahlöf, C; Maassen Van Den Brink, A | 1 |
| Goadsby, PJ; Mathias, CJ; Viana, M | 1 |
| Silberstein, S | 1 |
| Gelfand, AA; Goadsby, PJ | 1 |
| Csiba, L; Ficzere, A | 1 |
| Aubel, B; Bourgoin, S; Hamon, M; Kayser, V | 1 |
| Vaitkus, A; Vilionskis, A | 1 |
| Banwart, L; Hurtado, TR; Vandenberg, JT; Vinson, DR | 1 |
| Bigal, ME; Tepper, SJ | 1 |
| McCrory, DC; Silberstein, SD | 1 |
| Bell, WL; White, JR | 1 |
| Etienne, N; Guesnier, L; Hickel, P; Maroteaux, L; Schaerlinger, B | 1 |
| DALSGAARD-NIELSEN, T | 2 |
| CARPI, A; VIRNO, M | 1 |
| DRURY, JN | 1 |
| PERSICHETTI, C | 1 |
| HERSCHBERG, AD | 1 |
| Allain, H; Delgado, A; Géraud, G; Lantéri-Minet, M; Lucas, C; Pradalier, A | 1 |
| Lake, AE; Saper, JR; Swidan, SZ | 1 |
| Andrews, PL; Cheng, FH; Moreaux, B; Ngan, MP; Rudd, JA; Sam, TS; Wai, MK; Wan, C | 1 |
| Auvin, S; Cuvellier, JC; Joriot, S; Vallée, L | 1 |
| Brown, MD; Colman, I; Grafstein, E; Innes, GD; Roberts, TE; Rowe, BH | 1 |
| Josephs, KA; Stead, M | 1 |
| Berger, MY; Bruijn, JK; Damen, L; Koes, BW; Passchier, J; Verhagen, AP | 1 |
| Kabbouche, MA; Linder, SL | 1 |
| Charles, JA; Jotkowitz, S | 1 |
| Rozen, TD | 2 |
| Saper, JR; Silberstein, S | 1 |
| Dodick, D; Silberstein, S | 1 |
| Dodick, D; Rapoport, A; Saper, JR; Silberstein, S | 1 |
| Bradley, KC; Gebeline-Myers, C; Hopkins, MM; Silberstein, SD; Young, WB | 1 |
| Gano, D; Gerretsen, P; Silver, S | 1 |
| Nahas, SJ; Silberstein, SD | 1 |
| Bhatt, A; Farooq, MU; Kassab, MY; Macfalda, B; Masih, A; Naravetla, B | 1 |
| Huffmann, G | 1 |
| Aylward, M; Chazot, G; Maddock, J; Schott, B | 1 |
| Fanchamps, A; Müller-Schweinitzer, E | 1 |
| Bono, G; Lanfranchi, M; Manna, V; Manzoni, GC; Martucci, N; Mattesi, P; Micieli, G; Troiani, G | 1 |
| Conte, F; Fontanari, D; Perulli, L; Tambato, E; Toso, V; Zanetti, R | 1 |
| Eggers, C | 1 |
| Damasio, H | 1 |
| Aylward, M; Davies, DE; Jones, M; Maddock, J; Robinson, PR | 1 |
| D'Alessandro, R; Gamberini, G; Lozito, A; Sacquegna, T | 1 |
| Iaccarino, C; Mastrosimone, F | 1 |
| Albano, O; Attolini, E; Brucoli, C; Campanozzi, F; Centonze, V; Macinagrossa, G; Santoiemma, L | 1 |
| Anselmi, B; Del Bianco, PL; Franchi, G; Panconesi, A; Sicuteri, F | 1 |
| Saxena, PR; Spierings, EL | 2 |
| Durko, A; Głuszcz-Zielińska, A | 1 |
| Beubler, E | 1 |
| Titus, F | 2 |
| Alberca, R; Arenas, C; Casado, JL; Moreno, A; Serrano, V | 1 |
| Ferrari, MD; Haan, J | 1 |
| Scherl, ER; Wilson, JF | 1 |
| Ferrari, MD; Gijsman, HJ | 1 |
| Silberstein, SD; Young, WB | 1 |
| Goadsby, PJ; Kaube, H | 1 |
| Blumenthal, HJ; el-Raheb, M; Weisz, MA | 1 |
| Wilkinson, M | 2 |
| Lipton, RB; Silberstein, SD | 1 |
| Kumar, KL | 1 |
| Ford, R; Gallagher, RM; Hammerstad, J; Hoffert, M; Holtz, N; Kriegler, J; Peroutka, S; Saper, J; Vogel, B; Ziegler, D | 1 |
| Dalessio, D; Mathew, N; Sadowsky, C; Sheftell, F; Silberstein, SD; Solomon, S; Turkewitz, LJ; Winner, P | 2 |
| Landy, S; Lobo, BL | 1 |
| d'Allens, H; Henry, P | 1 |
| Doenicke, A; Hoernecke, R | 1 |
| Solomon, GD | 1 |
| Bax, WA; Ferrari, MD; Haan, J; Meijler, WJ; Timmerman, H; van Coevorden, RS | 1 |
| Edvinsson, L; Goadsby, PJ | 1 |
| Raskin, NH | 4 |
| Peroutka, SJ | 1 |
| Van Mil, JW | 1 |
| Wheeler, SD | 1 |
| Mathew, NT; Ravishankar, K; Sanin, LC | 1 |
| Le Force, B; Margul, B; Ricalde, O; Saper, J; Winner, P | 1 |
| Cajfinger, F; Guérard des Lauriers, A; Lacoste, JP; Peraudeau, P; Pradalier, A; Scheck, F | 1 |
| Ashford, E; Bertin, L; Bès, A; Pilgrim, AJ; Touchon, J | 1 |
| Couch, JR; Evans, MS; Ghobrial, MW; Naritoku, DK | 1 |
| Cabiac, MD; Dubray, C; Humbert, H; Lavène, D | 1 |
| Lucker, C; Mathew, NT; Tietjen, GE | 1 |
| Lambert, G; Michalicek, J | 1 |
| Crismon, ML; Dalmady-Israel, C; Fagan, SC; Gidal, BE; Graves, NM; Privitera, MD; Wagner, ML | 1 |
| Catarci, T; Cerbo, R | 1 |
| Gallagher, RM | 2 |
| Becker, WJ; Hoag, J; Riess, CM | 1 |
| Mathew, NT | 3 |
| Lipton, RB | 1 |
| Young, WB | 1 |
| Hämäläinen, ML; Hoppu, K; Santavuori, PR | 1 |
| Audinot-Bouchez, V; Chaput, C; Conte, C; Lavielle, G; Lochon, S; Millan, MJ; Newman-Tancredi, A; Verrièle, L | 1 |
| Kaplan, B; Swain, RA | 1 |
| Steurer, J | 1 |
| Bax, WA; Ferrari, MD; MaassenVanDenBrink, A; Reekers, M; Saxena, PR | 1 |
| Barton, CW; Carleton, SC; Chelly, JE; Chudnofsky, CR; Johnson, G; Morris, DL; Pietrzak, MP; Rhee, KJ; Rosenberg, J; Shesser, RF; Starkman, S; Van Valen, MK | 1 |
| Delemazure, B; Rozot, P; Sommer, S; Wagner, M; Xenard, L | 1 |
| Balda, BR; Hahne, T | 1 |
| Filatova, EG; Solov'eva, AD; Veĭn, AM | 1 |
| Kozma, CM; Lawrence, BJ; Payne, K | 1 |
| Logemann, CD; Rankin, LM | 1 |
| Bøe, MG; Monstad, P | 1 |
| Lutz, G; Pradalier, A; Vincent, D | 1 |
| Noth, J | 1 |
| Ashford, E; Boureau, F; Esperanca, P; Kappos, L; Schoenen, J | 1 |
| Krumholz, W; Menges, T; Ogal, H; Szalay, G | 1 |
| Alchaar, H; Besson, G; Billé-Turc, F; Bouillat, J; Brudon, F; Donnet, A; Galletti, P; Gastaut, JL; Lantéri-Minet, M; Maitre, M; Moene, Y; Rambaud, G; Rostini, C; Valance, J | 1 |
| Hargreaves, RJ; Williamson, DJ | 1 |
| Steiner, TJ; Tfelt-Hansen, P | 1 |
| Akhtar, ND; Murray, MA; Rothner, AD | 1 |
| Winner, P | 1 |
| Rothner, AD | 1 |
| Yamane, K | 1 |
| Hering, R; Korczyn, AD; Kuritzky, A; Treves, TA | 1 |
| Ferrari, MD | 1 |
| Autret, A; Mondon, K | 1 |
| Henry, P | 1 |
| Gupta, A; Rothner, AD | 1 |
| Diamond, S; Wenzel, R | 1 |
| Ullrich, J | 1 |
| Fanchamps, A | 2 |
| Heyck, H | 1 |
| Fozard, JR | 1 |
| Baust, W; Stürtzbecher, KH | 1 |
| Berde, B | 1 |
| Barolin, GS | 1 |
| Diamond, S | 1 |
| Edvinsson, L; Hardebo, JE; Owman, C; Svendgaard, NA | 1 |
| Hackaday, J | 1 |
| Miyazaki, T | 1 |
| Schwalb, H | 1 |
| Zicot, M | 1 |
| Victor, DI; Welch, RB | 1 |
| Herzberg, L; Lenman, JA | 1 |
| Liaño, H | 1 |
| den Boer, MO; Saxena, PR; Somers, JA | 1 |
| Wallasch, TM | 1 |
| Ollat, H | 1 |
| Buzzi, MG; Moskowitz, MA | 2 |
| Scott, AK | 1 |
| Schulman, EA; Silberstein, SD | 1 |
| Goldstein, J | 1 |
| Deliganis, AV; Peroutka, SJ | 1 |
| Goadsby, PJ; Jauslin, P; Lance, JW | 1 |
| Ambrosone, L; Cianciulli, GM; Iaquinto, G; Rambaldi, M; Rotiroti, D | 1 |
| Scott, G; Ward, TN | 1 |
| Brown, AM; Kaumann, AJ; Patch, TL | 1 |
| Bussone, G; Frediani, F; Grazzi, L; Mailland, F; Zanotti, A; Zappacosta, BM | 1 |
| Klapper, JA; Stanton, JS | 1 |
| Goadsby, PJ; Gundlach, AL | 1 |
| Rosenberg, SB; Schulman, EA | 1 |
| Arteaga Manjón-Cabez, R; Herranz Fernández, J; Lastra Martínez, L | 1 |
| Bremgartner, MF; Jenzer, G | 1 |
| Bell, R; Lee, MA; Montoya, D; Shuaib, A | 1 |
| Cavanna, M | 1 |
| Foley, KM; Hagen, N; Portenoy, RK | 1 |
| Backonja, M; Beinlich, B; Dulli, D; Schutta, HS | 1 |
| Soyka, D | 1 |
| Kunkel, RS | 1 |
| Bühling, M; Cruz, A; Seibel, K | 1 |
| Bousser, MG; Massiou, H | 2 |
| Prusiński, A | 1 |
| Edmeads, JG | 1 |
| Pfaffenrath, V; Reiter, M | 1 |
| Beck, B; Daniel, H | 1 |
| Bousser, MG; Chick, J; Fuseau, E; Soisson, T; Thevenet, R | 1 |
| Gerber, WD; Langohr, HD; Mangold, R; Reinecke, M | 1 |
| Aydin, N; Culcuoglu, A; Guvener, A; Karan, O; Tulunay, FC | 1 |
| Stein, M | 1 |
| Cauquil, J; Demarez, JP; Harmey, JL; Le Bastard, B; Neuman, M | 1 |
| Callaham, M; Raskin, N | 1 |
| Wörz, R | 1 |
| Vajnorský, J | 1 |
| Heuser, B; Middendorf, E | 1 |
| Höchter, W; Ottenjann, R; Seib, HJ; Wörmann, B | 1 |
| Alexander, K; Creutzig, A; Flöge, J; Kamin, K; Wagner, HH; Wannske, M | 1 |
| Durward, WF | 1 |
| Bresque, E; Lagoutte, F; Vérin, P; Vizdy, A | 1 |
88 review(s) available for dihydroergotamine and Migraine Disorders
| Article | Year |
|---|---|
Delivery of Dihydroergotamine Mesylate to the Upper Nasal Space for the Acute Treatment of Migraine: Technology in Action.
Topics: Administration, Inhalation; Administration, Intranasal; Dihydroergotamine; Humans; Mesylates; Migraine Disorders; Technology | 2022 |
Chronic Migraine: A Narrative Review on the Use of Botulinum Toxin with Clinical Indications and Future Directions.
Topics: Antipsychotic Agents; Botulinum Toxins, Type A; Calcitonin Gene-Related Peptide; Dihydroergotamine; Headache; Humans; Migraine Disorders; Nasal Sprays; Quality of Life; Treatment Outcome; Tryptamines | 2022 |
Variability in recurrence rates with acute treatments for migraine: why recurrence is not an appropriate outcome measure.
Topics: Calcitonin Gene-Related Peptide Receptor Antagonists; Dihydroergotamine; Headache; Humans; Migraine Disorders; Outcome Assessment, Health Care | 2022 |
INP104: a drug evaluation of a nonoral product for the acute treatment of migraine.
Topics: Dihydroergotamine; Drug Evaluation; Headache; Humans; Migraine Disorders | 2023 |
Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; History, 20th Century; History, 21st Century; Humans; Migraine Disorders | 2020 |
Intravenous Migraine Treatment in Children and Adolescents.
Topics: Administration, Intravenous; Adolescent; Akathisia, Drug-Induced; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Basal Ganglia Diseases; Child; Dexamethasone; Dihydroergotamine; Diphenhydramine; Dopamine Antagonists; Emergency Service, Hospital; Enzyme Inhibitors; Fluid Therapy; Glucocorticoids; Hospitalization; Humans; Hypnotics and Sedatives; Ketorolac; Lidocaine; Magnesium; Migraine Disorders; Prochlorperazine; Propofol; Valproic Acid; Vasoconstrictor Agents | 2020 |
The Changing Landscape of Pediatric Migraine Therapy: A Review.
Topics: Adolescent; Adrenergic beta-Antagonists; Amitriptyline; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Calcium Channel Blockers; Child; Cognitive Behavioral Therapy; Dihydroergotamine; Dopamine Antagonists; Fluid Therapy; Glucocorticoids; Headache Disorders, Secondary; Humans; Magnesium; Migraine Disorders; Nerve Block; Topiramate; Tryptamines; Valproic Acid | 2018 |
Oral methylergonovine maleate for refractory migraine and cluster headache prevention.
Topics: Administration, Oral; Adult; Analgesics, Non-Narcotic; Cluster Headache; Dihydroergotamine; Female; Humans; Methylergonovine; Migraine Disorders | 2013 |
Relatively slow and long-lasting antimigraine effect of dihydroergotamine is most likely due to basic pharmacological attributes of the drug: a review.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Time | 2013 |
What's new in the migraine attack treatment.
Topics: Analgesics; Calcitonin Gene-Related Peptide Receptor Antagonists; Dihydroergotamine; Humans; Migraine Disorders; Pain Management; Receptor, Serotonin, 5-HT1F; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan; Transcranial Magnetic Stimulation | 2013 |
Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine.
Topics: Analgesics, Non-Narcotic; Animals; Chemistry, Pharmaceutical; Dihydroergotamine; Humans; MEDLINE; Migraine Disorders | 2013 |
Orally inhaled dihydroergotamine: a review.
Topics: Administration, Inhalation; Administration, Oral; Analgesics, Non-Narcotic; Animals; Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders; Nebulizers and Vaporizers | 2013 |
Use of dihydroergotamine (DHE) should be restricted to no more than twice a week.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Headache Disorders, Secondary; Humans; Migraine Disorders | 2014 |
Acute Migraine Treatment in Adults.
Topics: Adult; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Caffeine; Dihydroergotamine; Drug Administration Schedule; Female; Humans; Male; Migraine Disorders; Pain Management; Serotonin Receptor Agonists; Treatment Outcome; Tryptamines | 2015 |
Acute Migraine Treatment.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Humans; Migraine Disorders; Tryptamines; Vasoconstrictor Agents | 2015 |
Drugs for the acute treatment of migraine in children and adolescents.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Dihydroergotamine; Humans; Ibuprofen; Migraine Disorders; Serotonin Receptor Agonists; Time Factors; Tryptamines | 2016 |
Inhaled drug therapy development for the treatment of migraine.
Topics: Administration, Inhalation; Animals; Dihydroergotamine; Humans; Loxapine; Migraine Disorders; Prochlorperazine | 2016 |
Is the Generally Held View That Intravenous Dihydroergotamine Is Effective in Migraine Based on Wrong "General Consensus" of One Trial? A Critical Review of the Trial and Subsequent Quotations.
Topics: Administration, Intravenous; Analgesics, Non-Narcotic; Dihydroergotamine; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Research Design | 2016 |
[Pathophysiology of migraine and clinical implications].
Topics: Analgesics; Brain; Cortical Spreading Depression; Cyclooxygenase 2 Inhibitors; Dihydroergotamine; Humans; Meninges; Migraine Disorders; Migraine with Aura; Neural Pathways; Neuronal Plasticity; Nociceptors; Risk Factors; Serotonin; Serotonin Receptor Agonists; Spinal Nerve Roots; Trigeminal Nerve; Tryptamines; Vasodilation | 2008 |
The relative efficacy of meperidine for the treatment of acute migraine: a meta-analysis of randomized controlled trials.
Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Humans; Ketorolac; Meperidine; Migraine Disorders; Randomized Controlled Trials as Topic | 2008 |
Migraine, allodynia, and implications for treatment.
Topics: Analgesics; Brain; Clinical Trials as Topic; Comorbidity; Cyclooxygenase Inhibitors; Dihydroergotamine; Humans; Hyperalgesia; Migraine Disorders; Trigeminal Nerve; Tryptamines | 2008 |
Dihydroergotamine: role in the treatment of migraine.
Topics: Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders | 2009 |
Acute treatment of migraine headaches.
Topics: Acute Disease; Analgesia; Anti-Inflammatory Agents; Dihydroergotamine; Female; Humans; Male; Migraine Disorders; Neuropharmacology; Outcome Assessment, Health Care; Patient Education as Topic; Physician-Patient Relations; Tryptamines | 2010 |
Meeting acute migraine treatment needs through novel treatment formulations.
Topics: Analgesics, Non-Narcotic; Diclofenac; Dihydroergotamine; Drug Administration Routes; Drug Delivery Systems; Drug Prescriptions; Humans; Migraine Disorders; Sumatriptan | 2010 |
New therapeutic developments in chronic migraine.
Topics: Analgesics; Anticonvulsants; Botulinum Toxins, Type A; Dihydroergotamine; Electric Stimulation Therapy; Headache Disorders; Humans; Migraine Disorders; Neuropharmacology; Preventive Medicine; Risk Factors | 2010 |
Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
Topics: Analgesics, Non-Narcotic; Animals; Dihydroergotamine; Female; Humans; Male; Migraine Disorders; Patient Satisfaction; Practice Guidelines as Topic; Quality of Life; Recurrence; Sex Factors | 2010 |
Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium.
Topics: Acute Disease; Analgesics, Non-Narcotic; Dihydroergotamine; Humans; Magnesium; MEDLINE; Migraine Disorders; Tryptamines | 2012 |
Sumatriptan (intranasal route of administration) for acute migraine attacks in adults.
Topics: Acute Disease; Administration, Intranasal; Adult; Dihydroergotamine; Female; Humans; Male; Migraine Disorders; Pain Management; Randomized Controlled Trials as Topic; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Triazoles; Tryptamines | 2012 |
Dihydroergotamine, ergotamine, methysergide and sumatriptan - basic science in relation to migraine treatment.
Topics: Animals; Dihydroergotamine; Ergotamine; Humans; Methysergide; Migraine Disorders; Sumatriptan; Treatment Outcome | 2012 |
MAP0004: dihydroergotamine mesylate inhalation aerosol for acute treatment of migraine.
Topics: Administration, Inhalation; Animals; Dihydroergotamine; Dopamine Agonists; Drug Delivery Systems; Humans; Metered Dose Inhalers; Migraine Disorders; Pulmonary Alveoli; Vasoconstrictor Agents | 2012 |
Treatment of pediatric migraine in the emergency room.
Topics: Adolescent; Age Distribution; Age of Onset; Analgesics; Antiemetics; Child; Child, Preschool; Dihydroergotamine; Disease Management; Dopamine Antagonists; Drug Therapy, Combination; Emergency Service, Hospital; Female; Fluid Therapy; Humans; Male; Metoclopramide; Migraine Disorders; Narcotics; Neuroimaging; Prevalence; Sex Distribution; Tryptamines; Valproic Acid; Vomiting | 2012 |
[Treatment of migraine in patients with hypertension and ischemic heart disease].
Topics: Adjuvants, Pharmaceutic; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Carbazoles; Contraindications; Dihydroergotamine; Dopamine Agonists; Ergotamine; Humans; Hypertension; Indoles; Migraine Disorders; Myocardial Ischemia; Oxazolidinones; Retrospective Studies; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines; Vasoconstrictor Agents | 2002 |
Ergotamine, dihydroergotamine: current uses and problems.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan | 2001 |
[The problems of migraine headache treatment].
Topics: Aged; Analgesics; Analgesics, Non-Narcotic; Aspirin; Dihydroergotamine; Female; Humans; Male; Methysergide; Migraine Disorders; Oxazolidinones; Serotonin Antagonists; Serotonin Receptor Agonists; Stress, Psychological; Sumatriptan; Time Factors; Tryptamines; Vasoconstrictor Agents | 2002 |
Ergotamine and dihydroergotamine: a review.
Topics: Dihydroergotamine; Dose-Response Relationship, Drug; Ergotamine; Humans; Migraine Disorders; Randomized Controlled Trials as Topic; Sumatriptan; Treatment Outcome | 2003 |
Ergotamine and dihydroergotamine: history, pharmacology, and efficacy.
Topics: Animals; Dihydroergotamine; Ergotamine; History, 19th Century; History, 20th Century; Humans; Migraine Disorders; Receptors, Serotonin; Treatment Outcome; United States; Vasoconstrictor Agents | 2003 |
MT 300--POZEN: dihydroergotamine mesylate injection.
Topics: Dihydroergotamine; Humans; Migraine Disorders; Nausea; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists | 2003 |
[Pharmacologic treatment of acute migraine attack in children].
Topics: Acetaminophen; Acute Disease; Administration, Intranasal; Administration, Oral; Adolescent; Age Factors; Analgesics, Non-Narcotic; Biofeedback, Psychology; Child; Dihydroergotamine; Humans; Ibuprofen; Injections, Intravenous; Life Style; Migraine Disorders; Relaxation Therapy; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 2005 |
Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature.
Topics: Adult; Antiemetics; Dihydroergotamine; Drug Therapy, Combination; Humans; Injections, Intravenous; Migraine Disorders; Randomized Controlled Trials as Topic | 2005 |
Symptomatic treatment of migraine in children: a systematic review of medication trials.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Child; Child, Preschool; Controlled Clinical Trials as Topic; Dihydroergotamine; Female; Humans; Ibuprofen; Ketorolac; Male; Migraine Disorders; Prochlorperazine; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan | 2005 |
Management of migraine in children and adolescents in the emergency department and inpatient setting.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Child; Dihydroergotamine; Dopamine Agents; Emergency Medical Services; Hospitalization; Humans; Migraine Disorders; Serotonin Receptor Agonists | 2005 |
Acute therapy for migraine headaches.
Topics: Antipsychotic Agents; Dihydroergotamine; Humans; Migraine Disorders; Narcotics; Time Factors; Tryptamines | 2006 |
Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine.
Topics: Analgesics, Non-Narcotic; Chronic Disease; Dihydroergotamine; Humans; Migraine Disorders | 2006 |
Central sensitization theory of migraine: clinical implications.
Topics: Analgesics, Non-Narcotic; Animals; Cyclooxygenase Inhibitors; Dihydroergotamine; Humans; Migraine Disorders; Nociceptors; Trigeminal Caudal Nucleus | 2006 |
DHE in the pharmacotherapy of migraine: potential for a larger role.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Headache Disorders, Secondary; Humans; Migraine Disorders; Prevalence | 2006 |
Acute treatment for migraine headache.
Topics: Adrenal Cortex Hormones; Barbiturates; Dihydroergotamine; Dopamine Antagonists; Humans; Migraine Disorders; Migraine with Aura; Tryptamines | 2007 |
Acute treatment of paediatric migraine: a meta-analysis of efficacy.
Topics: Acetaminophen; Adolescent; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Child; Dihydroergotamine; Drug Evaluation; Humans; Ibuprofen; Migraine Disorders; Oxazolidinones; Placebos; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines | 2008 |
[Migraine: dihydroergotamine nasal spray--an alternative].
Topics: Administration, Intranasal; Dihydroergotamine; Dose-Response Relationship, Drug; Humans; Metabolic Clearance Rate; Migraine Disorders; Treatment Outcome | 1995 |
[Treatment of the acute migraine attack].
Topics: Acute Disease; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 1995 |
[Status migrainosus].
Topics: Brain; Dihydroergotamine; Humans; Migraine Disorders; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 1995 |
Acute treatment of migraine attacks.
Topics: Adolescent; Adult; Analgesics; Child; Dihydroergotamine; Female; Humans; Male; Migraine Disorders; Pregnancy; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 1995 |
Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus. Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology.
Topics: Dihydroergotamine; Ergotamine; Humans; Migraine Disorders | 1995 |
Migraine treatment: the British perspective.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Sumatriptan; United Kingdom | 1994 |
Overview of diagnosis and treatment of migraine.
Topics: Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticonvulsants; Antidepressive Agents, Tricyclic; Calcium Channel Blockers; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Serotonin Antagonists; Sumatriptan | 1994 |
Recent advances in the acute management of migraine and cluster headaches.
Topics: Analgesics; Butorphanol; Capsaicin; Cluster Headache; Dihydroergotamine; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Sumatriptan; Tolmetin | 1994 |
Therapeutic advances in migraine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Female; Humans; Indoles; Male; Migraine Disorders; Receptors, Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan; Valproic Acid | 1993 |
Acute and prophylactic treatment of migraine: practical approaches and pharmacologic rationale.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Ergotamine; Humans; Indoles; Migraine Disorders; Phenothiazines; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan; Valproic Acid | 1993 |
5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine.
Topics: Adenylyl Cyclases; Dihydroergotamine; Humans; Indoles; Migraine Disorders; Receptors, Serotonin; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan | 1993 |
Current developments in neurology, Part I: Advances in the pharmacotherapy of headache, epilepsy, and multiple sclerosis.
Topics: Adjuvants, Immunologic; Administration, Intranasal; Administration, Oral; Anticonvulsants; Dihydroergotamine; Epilepsies, Partial; GABA Agonists; Humans; Injections, Spinal; Interferon beta-1a; Interferon beta-1b; Interferon-beta; Migraine Disorders; Multiple Sclerosis; Vasoconstrictor Agents | 1996 |
The pharmacology of ergotamine and dihydroergotamine.
Topics: Analgesics, Non-Narcotic; Body Fluids; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Receptors, Serotonin; Structure-Activity Relationship | 1997 |
Dosing and administration of ergotamine tartrate and dihydroergotamine.
Topics: Analgesics, Non-Narcotic; Cluster Headache; Dihydroergotamine; Dosage Forms; Ergotamine; Humans; Migraine Disorders; Nausea; Suppositories; Tablets; Vomiting | 1997 |
Ergotamine tartrate and dihydroergotamine mesylate: safety profiles.
Topics: Administration, Intranasal; Analgesics, Non-Narcotic; Animals; Consumer Product Safety; Dihydroergotamine; Drug Monitoring; Ergotamine; Humans; Migraine Disorders; Nausea; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic | 1997 |
Serotonin 1D (5-HT1D) agonists and other agents in acute migraine.
Topics: Acute Disease; Analgesics, Non-Narcotic; Cluster Headache; Dihydroergotamine; Drug Interactions; Humans; Migraine Disorders; Recurrence; Serotonin Receptor Agonists; Sumatriptan; Treatment Outcome; Vasoconstrictor Agents | 1997 |
Diagnosis, prophylaxis, and treatment of headaches in the athlete.
Topics: Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; Chronic Disease; Cluster Headache; Dihydroergotamine; Female; GABA Agents; Headache; Humans; Male; Migraine Disorders; Nortriptyline; Physical Exertion; Psychomotor Performance; Recurrence; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sports; Sumatriptan; Tension-Type Headache; Valproic Acid; Vasodilator Agents; Verapamil | 1997 |
Newer intranasal migraine medications.
Topics: Administration, Intranasal; Administration, Oral; Analgesics, Non-Narcotic; Clinical Trials as Topic; Dihydroergotamine; Half-Life; Humans; Indoles; Migraine Disorders; Oxazoles; Oxazolidinones; Piperidines; Recurrence; Serotonin Receptor Agonists; Sumatriptan; Triazoles; Tryptamines | 2000 |
Neurogenic inflammation in the context of migraine.
Topics: Animals; Blood Proteins; Bosentan; Calcitonin Gene-Related Peptide; Capillary Permeability; Dihydroergotamine; Dura Mater; Humans; Migraine Disorders; Narcotics; Neurogenic Inflammation; Neurokinin-1 Receptor Antagonists; Pyrrolidines; Receptor, Serotonin, 5-HT1D; Receptor, Serotonin, 5-HT1F; Receptors, Neurokinin-1; Receptors, Serotonin; Serotonin Receptor Agonists; Skull; Sulfonamides; Sumatriptan; Trigeminal Nerve; Vasoconstrictor Agents; Vasodilation | 2001 |
Triptans in childhood and adolescence.
Topics: Administration, Intranasal; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Clinical Trials as Topic; Dihydroergotamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Migraine Disorders; Serotonin Receptor Agonists; Treatment Failure; Vasoconstrictor Agents | 2001 |
Complicated migraine and migraine variants.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Diagnosis, Differential; Dihydroergotamine; Female; Humans; Male; Migraine Disorders; Sumatriptan | 2001 |
[Migraine: selection of therapeutic agents to be applied during its attack].
Topics: Analgesics; Antiemetics; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Sumatriptan | 2001 |
Treatment of childhood headaches.
Topics: Acute Disease; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; Dihydroergotamine; Dopamine Antagonists; Double-Blind Method; Headache; Humans; Infant; Meninges; Migraine Disorders; Models, Theoretical; Patient Care Management; Prostaglandin Antagonists; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Tension-Type Headache; Trigeminal Nerve; Vasoconstrictor Agents | 2001 |
Practical approaches to migraine management.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Analgesics, Opioid; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders; Psychotropic Drugs; Secondary Prevention; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 2002 |
The animal pharmacology of drugs used in the treatment of migraine.
Topics: Acetaminophen; Adrenergic alpha-Antagonists; Analgesics; Animals; Aspirin; Caffeine; Clonidine; Cyproheptadine; Dihydroergotamine; Ergotamine; Humans; Methysergide; Migraine Disorders; Monoamine Oxidase Inhibitors; Muscle, Smooth; Pizotyline; Serotonin Antagonists; Sympathetic Nervous System; Synaptic Transmission; Tryptamines; Vagus Nerve; Vasoconstrictor Agents; Vasodilator Agents | 1975 |
[Classification, pathogenesis and drug therapy of migraine and related forms of headache].
Topics: Adrenergic beta-Antagonists; Animals; Caffeine; Clonidine; Dihydroergotamine; Drug Synergism; Epinephrine; Ergotamine; Headache; Histamine; Humans; Methysergide; Mice; Migraine Disorders; Norepinephrine; Pizotyline; Serotonin | 1975 |
Pharmacology of ergot alkaloids in clinical use.
Topics: Animals; Brain Diseases; Bromocriptine; Dihydroergotamine; Dihydroergotoxine; Dopamine Antagonists; Ergot Alkaloids; Ergotamine; Female; Humans; Methysergide; Migraine Disorders; Parkinson Disease; Pituitary Gland; Prolactin; Receptors, Adrenergic; Receptors, Dopamine; Uterus; Vasoconstriction | 1978 |
[Current treatment of migraine].
Topics: Adult; Child; Dihydroergotamine; Ergotamine; Female; Humans; Indoles; Male; Methysergide; Metoclopramide; Middle Aged; Migraine Disorders; Sulfonamides; Sumatriptan; Time Factors; Vasoconstrictor Agents | 1992 |
[Drug-induced headache].
Topics: Analgesics; Analgesics, Opioid; Dihydroergotamine; Ergotamine; Headache; Humans; Migraine Disorders | 1992 |
[Serotonin agonists and antagonists in migraine].
Topics: Benzoxepins; Contraindications; Cyproheptadine; Dihydroergotamine; Ergotamine; Histamine H1 Antagonists; Humans; Indoles; Methysergide; Migraine Disorders; Phenothiazines; Pizotyline; Receptors, Serotonin; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1992 |
The trigemino-vascular system and migraine.
Topics: Blood Proteins; Calcitonin Gene-Related Peptide; Cerebrovascular Disorders; Cranial Nerve Diseases; Dihydroergotamine; Dura Mater; Humans; Indoles; Migraine Disorders; Receptors, Serotonin; Substance P; Sulfonamides; Sumatriptan; Trigeminal Nerve; Vasoconstrictor Agents | 1992 |
Dihydroergotamine: a review of its use in the treatment of migraine and other headaches.
Topics: Dihydroergotamine; Headache; Humans; Migraine Disorders | 1992 |
Symptomatic and prophylactic treatment of migraine and tension-type headache.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Drug Therapy, Combination; Ergot Alkaloids; Headache; Humans; Migraine Disorders | 1992 |
Ergot pharmacology and alternative delivery systems for ergotamine derivatives.
Topics: Dihydroergotamine; Drug Administration Routes; Humans; Migraine Disorders | 1992 |
[Flunarizine and dihydroergotamine in the treatment of migraine in children].
Topics: Age Factors; Child; Child, Preschool; Dihydroergotamine; Dose-Response Relationship, Drug; Flunarizine; Humans; Migraine Disorders; Parents | 1990 |
Modern pharmacotherapy of migraine.
Topics: Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Chlorpromazine; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Prochlorperazine; Valproic Acid | 1990 |
[Therapy of headache].
Topics: Cluster Headache; Dextropropoxyphene; Dihydroergotamine; Domperidone; Ergotamine; Headache; Humans; Methysergide; Migraine Disorders; Pizotyline; Prednisolone; Prednisone; Vascular Headaches | 1989 |
Pharmacologic management of migraine--1985.
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Anti-Inflammatory Agents; Calcium Channel Blockers; Dihydroergotamine; Humans; Lithium; Lithium Carbonate; Methysergide; Metoclopramide; Migraine Disorders; Receptors, Adrenergic, alpha; Vasodilator Agents | 1985 |
Monotherapy or polytherapy in migraine.
Topics: Barbiturates; Clonidine; Dihydroergotamine; Drug Combinations; Humans; Migraine Disorders; Pizotyline | 1987 |
Migraine.
Topics: Acute Disease; Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Analgesics; Calcium Channel Blockers; Chlorpromazine; Dihydroergotamine; Ergotamine; Humans; Methysergide; Migraine Disorders; Narcotics; Pizotyline | 1988 |
[Drug therapy of migraine].
Topics: Adrenergic beta-Antagonists; Analgesics; Antiemetics; Cerebrovascular Circulation; Dihydroergotamine; Humans; Locus Coeruleus; Methysergide; Migraine Disorders; Raphe Nuclei | 1988 |
46 trial(s) available for dihydroergotamine and Migraine Disorders
| Article | Year |
|---|---|
Assessing acute systemic effects of an inhaled drug with serial echocardiography: a placebo-controlled comparison of inhaled and intravenous dihydroergotamine.
Topics: Administration, Inhalation; Administration, Intravenous; Adolescent; Adult; Cross-Over Studies; Dihydroergotamine; Double-Blind Method; Echocardiography; Female; Humans; Male; Metered Dose Inhalers; Middle Aged; Migraine Disorders; Pulmonary Artery; Systole | 2013 |
Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics.
Topics: Administration, Inhalation; Administration, Oral; Adolescent; Adult; Analgesics, Non-Narcotic; Asthma; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebos | 2008 |
A randomized, double blind, placebo-controlled study of MAP0004 in adult patients with migraine.
Topics: Administration, Inhalation; Adolescent; Adult; Analgesics, Non-Narcotic; Dihydroergotamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain Measurement; Time Factors; Treatment Outcome; Young Adult | 2009 |
Outpatient home-based continuous intravenous dihydroergotamine therapy for intractable migraine.
Topics: Adolescent; Adult; Analgesics, Non-Narcotic; Dihydroergotamine; Female; Headache Disorders; Home Infusion Therapy; Humans; Infusions, Intravenous; Male; Migraine Disorders; Pain, Intractable; Prospective Studies; Young Adult | 2010 |
MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebo Effect; Treatment Outcome; Young Adult | 2011 |
MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.
Topics: Administration, Inhalation; Adolescent; Adult; Dihydroergotamine; Female; Humans; Male; Middle Aged; Migraine Disorders; Patient Selection; Time Factors; Treatment Outcome; Vasoconstrictor Agents; Young Adult | 2011 |
Efficacy and safety of MAP0004, orally inhaled DHE in treating migraines with and without allodynia.
Topics: Administration, Inhalation; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Dihydroergotamine; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperalgesia; Male; Middle Aged; Migraine Disorders; Pain Measurement; Surveys and Questionnaires; Treatment Outcome; Young Adult | 2012 |
Lack of drug interaction between the migraine drug MAP0004 (orally inhaled dihydroergotamine) and a CYP3A4 inhibitor in humans.
Topics: 14-alpha Demethylase Inhibitors; Administration, Inhalation; Adult; Chemistry, Pharmaceutical; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dihydroergotamine; Drug Interactions; Female; Humans; Ketoconazole; Male; Migraine Disorders; Vasoconstrictor Agents; Young Adult | 2012 |
MT 300. Dihydroergotamine mesylate injection - POZEN.
Topics: Dihydroergotamine; Humans; Injections; Migraine Disorders; Nausea; Time Factors | 2003 |
The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.
Topics: Adolescent; Adult; Aged; Dihydroergotamine; Double-Blind Method; Humans; Male; Middle Aged; Migraine Disorders; Primary Health Care; Quality of Life; Time Factors; Treatment Outcome; Vasoconstrictor Agents | 2004 |
Observations of the "carry-over effect" following successful termination of chronic migraine in the adolescent with short-term dihydroergotamine, dexamethasone and hydroxyzine: a pilot study.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Anti-Inflammatory Agents; Brain; Chronic Disease; Dexamethasone; Dihydroergotamine; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Female; Headache Disorders; Histamine H1 Antagonists; Humans; Hydroxyzine; Infusions, Parenteral; Male; Migraine Disorders; Pilot Projects; Treatment Outcome; Vasoconstrictor Agents | 2005 |
Dihydroergotamine for early and late treatment of migraine with cutaneous allodynia: an open-label pilot trial.
Topics: Adult; Analgesics, Non-Narcotic; Dihydroergotamine; Humans; Hyperalgesia; Injections, Intramuscular; Male; Middle Aged; Migraine Disorders; Physical Stimulation; Pilot Projects; Time Factors; Treatment Outcome | 2007 |
[Treatment of morning migraine. Clinical and biokinetic correlation of programmed-release dihydroergotamine].
Topics: Adolescent; Adult; Circadian Rhythm; Clinical Trials as Topic; Delayed-Action Preparations; Dihydroergotamine; Double-Blind Method; Female; Humans; Kinetics; Male; Middle Aged; Migraine Disorders; Solutions | 1984 |
Ergot derivatives in the prophylaxis of migraine: a multicentric study with a timed-release dihydroergotamine formulation.
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Random Allocation; Recurrence | 1983 |
Planned release dihydroergotamine in common migraine and "tension-vascular headache": multicentre clinical trial.
Topics: Adolescent; Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dihydroergotamine; Female; Humans; Male; Middle Aged; Migraine Disorders; Vascular Headaches | 1983 |
Efficacy, safety, and tolerability of dihydroergotamine nasal spray as monotherapy in the treatment of acute migraine. Dihydroergotamine Nasal Spray Multicenter Investigators.
Topics: Acute Disease; Adolescent; Adult; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Time Factors | 1995 |
Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine.
Topics: Acute Disease; Adult; Ambulatory Care; Dihydroergotamine; Double-Blind Method; Drug Combinations; Female; Humans; Male; Meperidine; Metoclopramide; Middle Aged; Migraine Disorders; Promethazine; Prospective Studies | 1995 |
Dihydroergotamine nasal spray for the acute treatment of migraine.
Topics: Administration, Intranasal; Adolescent; Adult; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders | 1994 |
Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine.
Topics: Acute Disease; Adolescent; Adult; Aged; Antiemetics; Child; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Incidence; Injections, Intramuscular; Male; Migraine Disorders; Nausea; Office Visits; Prospective Studies; Time Factors | 1994 |
Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Dihydroergotamine; Double-Blind Method; Drug Interactions; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Sumatriptan | 1993 |
[Treatment of migraine attacks: combination of dihydroergotamine tartrate and paracetamol in comparison with individual drugs and placebo].
Topics: Acetaminophen; Adolescent; Adult; Aged; Dihydroergotamine; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Migraine Disorders; Pain Measurement | 1993 |
A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine.
Topics: Acute Disease; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Dihydroergotamine; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Prospective Studies; Recurrence; Serotonin Receptor Agonists; Sumatriptan | 1996 |
[Calcium carbasalate-metoclopramide combination versus dihydroergotamine in the treatment of migraine attacks].
Topics: Administration, Oral; Adolescent; Adult; Analgesics, Non-Narcotic; Cross-Sectional Studies; Dihydroergotamine; Dopamine Antagonists; Double-Blind Method; Female; Humans; Male; Metoclopramide; Middle Aged; Migraine Disorders; Placebos | 1995 |
A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine.
Topics: Administration, Intranasal; Adult; Dihydroergotamine; Double-Blind Method; Female; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Sumatriptan | 1996 |
Human pharmacokinetics of dihydroergotamine administered by nasal spray.
Topics: Acute Disease; Administration, Intranasal; Adult; Analgesics, Non-Narcotic; Area Under Curve; Biological Availability; Dihydroergotamine; Dose-Response Relationship, Drug; Female; Humans; Injections, Intramuscular; Linear Models; Male; Middle Aged; Migraine Disorders; Reference Values; Rhinitis | 1996 |
Acute treatment of migraine with dihydroergotamine nasal spray. Dihydroergotamine Working Group.
Topics: Acute Disease; Administration, Intranasal; Adolescent; Adult; Aged; Dihydroergotamine; Double-Blind Method; Female; Hallucinations; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Placebos; Self Administration | 1996 |
Oral dihydroergotamine for therapy-resistant migraine attacks in children.
Topics: Administration, Oral; Analgesics, Non-Narcotic; Child; Cross-Over Studies; Dihydroergotamine; Double-Blind Method; Drug Resistance; Female; Humans; Male; Migraine Disorders; Retreatment; Treatment Outcome | 1997 |
Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache.
Topics: Acute Disease; Adolescent; Adult; Analgesics, Non-Narcotic; Analgesics, Opioid; Antiemetics; Dihydroergotamine; Double-Blind Method; Drug Combinations; Emergency Service, Hospital; Female; Follow-Up Studies; Humans; Hydroxyzine; Injections, Intramuscular; Male; Meperidine; Middle Aged; Migraine Disorders; Nausea; Pain Measurement; Prospective Studies; Time Factors | 1998 |
Comparing dihydroergotamine mesylate and sumatriptan in the management of acute migraine. A retrospective cost-efficacy analysis.
Topics: Adolescent; Adult; Aged; Cost-Benefit Analysis; Dihydroergotamine; Humans; Middle Aged; Migraine Disorders; Retrospective Studies; Sumatriptan; Vasoconstrictor Agents | 1996 |
A clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
Topics: Adult; Aged; Belgium; Cross-Over Studies; Dihydroergotamine; Double-Blind Method; Female; France; Humans; Male; Middle Aged; Migraine Disorders; Portugal; Sumatriptan; Switzerland; Vasoconstrictor Agents | 2000 |
Dihydroergotamine nasal spray in the treatment of acute migraine.
Topics: Acute Disease; Administration, Intranasal; Adult; Analgesics, Non-Narcotic; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Migraine Disorders; Nebulizers and Vaporizers; Treatment Outcome | 1998 |
[Management of migraine using acupuncture in a double-blind study].
Topics: Acupuncture Therapy; Adult; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Migraine Disorders | 1978 |
Dihydroergokryptine versus dihydroergotamine in migraine prophylaxis: a double-blind clinical trial.
Topics: Adult; Analgesics; Dihydroergotamine; Dihydroergotoxine; Double-Blind Method; Female; Humans; Male; Middle Aged; Migraine Disorders; Time Factors | 1991 |
[Flunarizine and dihydroergotamine in the treatment of migraine in children].
Topics: Age Factors; Child; Child, Preschool; Dihydroergotamine; Dose-Response Relationship, Drug; Flunarizine; Humans; Migraine Disorders; Parents | 1990 |
[Dihydroergotamine as a nasal spray in the therapy of migraine attacks. Efficacy and tolerance].
Topics: Administration, Intranasal; Adult; Aged; Aged, 80 and over; Child; Dihydroergotamine; Drug Evaluation; Female; Humans; Male; Middle Aged; Migraine Disorders; Multicenter Studies as Topic; Nebulizers and Vaporizers | 1990 |
A comparative trial of three agents in the treatment of acute migraine headache.
Topics: Adult; Chlorpromazine; Dihydroergotamine; Emergencies; Follow-Up Studies; Humans; Infusions, Intravenous; Lidocaine; Migraine Disorders; Pain Measurement | 1990 |
DHE-45 for acute migraine.
Topics: Acute Disease; Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders; Research Design | 1989 |
[Double blind study of migraine therapy with etilefrine pivalate].
Topics: Adult; Aged; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Etilefrine; Female; Humans; Male; Middle Aged; Migraine Disorders; Phenylephrine; Random Allocation; Time Factors | 1985 |
Combined low-dose acetylsalicylic acid and dihydroergotamine in migraine prophylaxis. A double-blind, placebo-controlled crossover study.
Topics: Adolescent; Adult; Aged; Aspirin; Dihydroergotamine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Combinations; Female; Humans; Male; Middle Aged; Migraine Disorders; Placebos | 1988 |
[Dihydroergotamine and flunarizine in the prevention of migraine. A comparative double-blind study].
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dihydroergotamine; Double-Blind Method; Female; Flunarizine; Humans; Male; Middle Aged; Migraine Disorders | 1988 |
Dihydroergotamine nasal spray during migraine attacks. A double-blind crossover study with placebo.
Topics: Administration, Intranasal; Adolescent; Adult; Clinical Trials as Topic; Dihydroergotamine; Double-Blind Method; Female; Humans; Male; Migraine Disorders | 1987 |
Prevention of migraine attacks through the use of dihydroergotamine.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Delayed-Action Preparations; Dihydroergotamine; Double-Blind Method; Humans; Middle Aged; Migraine Disorders; Random Allocation; Time Factors | 1986 |
A controlled study of dihydroergotamine in the treatment of acute migraine headache.
Topics: Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders | 1986 |
Repetitive intravenous dihydroergotamine as therapy for intractable migraine.
Topics: Adult; Aged; Chronic Disease; Clinical Trials as Topic; Diazepam; Dihydroergotamine; Female; Humans; Injections; Injections, Intravenous; Male; Middle Aged; Migraine Disorders; Suppositories; Time Factors | 1986 |
[Prevention of migraine with retard dihydroergotamine. Results of a multicenter study in 643 patients].
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Dihydroergotamine; Female; Humans; Male; Migraine Disorders | 1986 |
[Migraine prevention with dihydroergotamine].
Topics: Adult; Clinical Trials as Topic; Delayed-Action Preparations; Dihydroergotamine; Double-Blind Method; Female; Humans; Middle Aged; Migraine Disorders; Random Allocation | 1985 |
147 other study(ies) available for dihydroergotamine and Migraine Disorders
| Article | Year |
|---|---|
Alniditan, a new 5-hydroxytryptamine1D agonist and migraine-abortive agent: ligand-binding properties of human 5-hydroxytryptamine1D alpha, human 5-hydroxytryptamine1D beta, and calf 5-hydroxytryptamine1D receptors investigated with [3H]5-hydroxytryptamin
Topics: Animals; Benzopyrans; Cattle; Cloning, Molecular; Glioma; HeLa Cells; Humans; Mice; Migraine Disorders; Propylamines; Protein Binding; Pyrimidines; Radioligand Assay; Receptors, Serotonin; Serotonin Receptor Agonists; Signal Transduction; Tritium; Tumor Cells, Cultured; Vasoconstrictor Agents | 1996 |
Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.
Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adolescent; Adult; Case-Control Studies; Child; Child, Preschool; Dihydroergotamine; Female; Follow-Up Studies; Humans; Infant; Infant, Low Birth Weight; Infant, Newborn; Migraine Disorders; Pregnancy; Premature Birth; Prospective Studies; Quebec; Tryptamines; Young Adult | 2021 |
A new dihydroergotamine nasal spray (Trudhesa) for migraine.
Topics: Administration, Intranasal; Dihydroergotamine; Humans; Migraine Disorders; Nasal Sprays; Vasoconstrictor Agents | 2021 |
Peripheral Nerve Blocks: A Tool for Inpatient Pediatric Status Migrainosus.
Topics: Child; Dihydroergotamine; Humans; Inpatients; Migraine Disorders; Pain; Peripheral Nerves; Retrospective Studies | 2023 |
Observational Analysis of the Costs Associated with Acute Treatment of Breakthrough Migraine Attacks in Medicaid Patients Using Preventive Therapies.
Topics: Antibodies, Monoclonal; Calcitonin Gene-Related Peptide; Dihydroergotamine; Humans; Medicaid; Migraine Disorders; Tryptamines | 2023 |
Enhancing Outpatient Dihydroergotamine Infusion With Interdisciplinary Care to Treat Refractory Pediatric Migraine: Preliminary Outcomes From the Comprehensive Aggressive Migraine Protocol ("CAMP").
Topics: Adolescent; Ambulatory Care; Analgesics, Non-Narcotic; Aromatherapy; Child; Clinical Protocols; Combined Modality Therapy; Dihydroergotamine; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Massage; Migraine Disorders; Outcome Assessment, Health Care; Outpatient Clinics, Hospital; Pilot Projects; Psychotherapy; Retrospective Studies; Schools; Social Support | 2020 |
Could inhaled drug formulations be the future of acute migraine treatment?
Topics: Administration, Inhalation; Administration, Intranasal; Blood-Brain Barrier; Dihydroergotamine; Dopamine Agonists; Humans; Metered Dose Inhalers; Migraine Disorders; Oxazolidinones; Serotonin 5-HT1 Receptor Agonists; Tryptamines | 2019 |
Implementation of an Intravenous Dihydroergotamine Protocol for Refractory Migraine in Children.
Topics: Administration, Intravenous; Adolescent; Analgesics, Non-Narcotic; Child; Clinical Protocols; Dihydroergotamine; Female; Humans; Male; Migraine Disorders; Outcome Assessment, Health Care; Retrospective Studies | 2020 |
The status of intravenous dihydroergotamine for pediatric headache: Status migrainosus and beyond.
Topics: Administration, Intravenous; Child; Dihydroergotamine; Headache; Humans; Migraine Disorders | 2021 |
Everything old is new again.
Topics: Adult; Calcitonin Gene-Related Peptide Receptor Antagonists; Dihydroergotamine; Humans; Migraine Disorders; Piperidines; Pyridines; Vasoconstrictor Agents | 2021 |
Dihydroergotamine mesylate-loaded dissolving microneedle patch made of polyvinylpyrrolidone for management of acute migraine therapy.
Topics: Acute Pain; Analgesics, Non-Narcotic; Animals; Biological Availability; Dihydroergotamine; Drug Delivery Systems; Drug Liberation; Injections, Subcutaneous; Male; Microinjections; Migraine Disorders; Needles; Povidone; Rats, Hairless; Rats, Sprague-Dawley; Skin; Solubility; Swine | 2017 |
Diagnosis and treatment of migraine in the patient with depression.
Topics: Comorbidity; Depression; Dihydroergotamine; Disease Management; Humans; Migraine Disorders; Practice Guidelines as Topic; Serotonin 5-HT1 Receptor Agonists | 2018 |
Development and in vitro/in vivo evaluation of dihydroergotamine mesylate loaded maltodextrin-pullulan sublingual films.
Topics: Administration, Sublingual; Animals; Biological Availability; Dihydroergotamine; Drug Compounding; Drug Evaluation, Preclinical; Drug Liberation; Excipients; Female; Glucans; Injections, Intravenous; Migraine Disorders; Polysaccharides; Rabbits; Solubility; Time Factors; Vasoconstrictor Agents | 2019 |
Intravenous dihydroergotamine therapy for pediatric abdominal migraines.
Topics: Adolescent; Dihydroergotamine; Female; Humans; Infusions, Intravenous; Male; Migraine Disorders; Vasoconstrictor Agents; Young Adult | 2013 |
Treatment of acute migraine in the emergency department.
Topics: Acetaminophen; Acute Disease; Analgesics, Non-Narcotic; Analgesics, Opioid; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dexamethasone; Dihydroergotamine; Droperidol; Emergency Service, Hospital; Evidence-Based Emergency Medicine; Fluid Therapy; Haloperidol; Humans; Migraine Disorders; Serotonin 5-HT1 Receptor Agonists | 2014 |
Is orally inhaled dihydroergotamine (DHE) equivalent in efficacy in migraine to intravenous DHE?
Topics: Administration, Inhalation; Administration, Intravenous; Administration, Oral; Dihydroergotamine; Humans; Migraine Disorders; Treatment Outcome | 2014 |
The Use of a Pediatric Migraine Practice Guideline in an Emergency Department Setting.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dihydroergotamine; Diphenhydramine; Emergency Service, Hospital; Female; Guideline Adherence; Humans; Hypnotics and Sedatives; Ketorolac; Length of Stay; Male; Metoclopramide; Migraine Disorders; Pain Management; Pain Measurement; Practice Guidelines as Topic; Prochlorperazine; Treatment Outcome; Vasoconstrictor Agents | 2016 |
Movement Disorders From the Use of Metoclopramide and Other Antiemetics in the Treatment of Migraine.
Topics: Adult; Dihydroergotamine; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Expert Testimony; Female; Humans; Metoclopramide; Migraine Disorders; Movement Disorders | 2016 |
Cerebral reactivity in migraine patients measured with functional near-infrared spectroscopy.
Topics: Adult; Analgesics, Non-Narcotic; Cerebrovascular Circulation; Dihydroergotamine; Female; Humans; Magnesium Sulfate; Male; Middle Aged; Migraine Disorders; Self Report; Skin; Spectroscopy, Near-Infrared; Valproic Acid; Vasoconstrictor Agents | 2015 |
Comment: Outcomes of migraine therapy with IV dihydroergotamine.
Topics: Dihydroergotamine; Female; Headache; Humans; Male; Migraine Disorders | 2016 |
Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; California; Causality; Chronic Disease; Comorbidity; Dihydroergotamine; Female; Headache; Humans; Incidence; Injections, Intravenous; Male; Middle Aged; Migraine Disorders; Retrospective Studies; Risk Factors; Treatment Outcome; Vasoconstrictor Agents; Young Adult | 2016 |
Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine.
Topics: Adult; Blood-Brain Barrier; Dihydroergotamine; Female; Humans; Male; Middle Aged; Migraine Disorders; Nitroglycerin; Positron-Emission Tomography; Vasoconstrictor Agents; Vasodilator Agents | 2016 |
Aprepitant for the management of nausea with inpatient IV dihydroergotamine.
Topics: Administration, Intravenous; Administration, Oral; Analgesics, Non-Narcotic; Antiemetics; Aprepitant; Dihydroergotamine; Humans; Inpatients; Migraine Disorders; Morpholines; Nausea; Prospective Studies; Retrospective Studies; Treatment Outcome | 2016 |
Inpatient Pediatric Migraine Treatment: Does Choice of Abortive Therapy Affect Length of Stay?
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Dihydroergotamine; Dopamine Antagonists; Female; Hospitalization; Humans; Length of Stay; Male; Migraine Disorders; Retrospective Studies | 2016 |
Journal Club: Exacerbation of headache during dihydroergotamine for chronic migraine does not alter outcome.
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Headache; Humans; Migraine Disorders | 2016 |
Safety of domperidone in treating nausea associated with dihydroergotamine infusion and headache.
Topics: Adolescent; Adult; Aged; Antiemetics; Dihydroergotamine; Domperidone; Female; Headache; Humans; Male; Middle Aged; Migraine Disorders; Nausea; Prospective Studies; Retrospective Studies; Young Adult | 2016 |
Inpatient treatment of status migraine with dihydroergotamine in children and adolescents.
Topics: Adolescent; Analgesics, Non-Narcotic; Child; Dihydroergotamine; Female; Humans; Inpatients; Male; Migraine Disorders; Treatment Outcome | 2009 |
Drug dependence associated with triptans and ergot derivatives: a case/non-case study.
Topics: Claviceps; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Oxazolidinones; Piperidines; Pyrrolidines; Risk; Substance-Related Disorders; Sumatriptan; Tryptamines | 2010 |
Migraine: its treatment with dihydroergotamine (D.H.E. 45).
Topics: Dihydroergotamine; Humans; Migraine Disorders | 1947 |
Dihydroergotamine (D.H.E. 45), a new and effective drug in the treatment of migraine.
Topics: Claviceps; Dihydroergotamine; Ergonovine; Ergot Alkaloids; Migraine Disorders | 1946 |
Migraine headache; treatment of 51 patients with dihydroergotamine.
Topics: Dihydroergotamine; Humans; Migraine Disorders; Vasoconstrictor Agents | 1947 |
DHE repression of ATP-mediated sensitization of trigeminal ganglion neurons.
Topics: Adenosine Triphosphate; Animals; Calcitonin Gene-Related Peptide; Cells, Cultured; Dihydroergotamine; Down-Regulation; Female; Migraine Disorders; Neural Inhibition; Rats; Rats, Sprague-Dawley; Sensory Receptor Cells; Trigeminal Ganglion; Vasoconstrictor Agents | 2010 |
Comparison of dihydroergotamine, ergotamine and other agents in the treatment of migraine.
Topics: Claviceps; Dihydroergotamine; Ergonovine; Ergot Alkaloids; Ergotamine; Migraine Disorders | 1946 |
D.H.E. 45 (dihydroergotamine) a new drug in the treatment of migraine.
Topics: Dihydroergotamine; Ergonovine; Ergot Alkaloids; Migraine Disorders | 1946 |
Dihydroergotamine in the treatment of migraine; preliminary clinical observations.
Topics: Claviceps; Dihydroergotamine; Ergonovine; Ergot Alkaloids; Humans; Migraine Disorders | 1945 |
DIHYDROERGOTAMINE and histamine for migraine.
Topics: Dihydroergotamine; Histamine; Humans; Migraine Disorders | 1946 |
Commentary.
Topics: Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders; Serotonin 5-HT1 Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 2011 |
Refractory caffeine and ergot-induced cervico-cerebral vasospasm and stroke treated with combined medical and endovascular approach.
Topics: Adult; Caffeine; Cerebral Angiography; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Magnetic Resonance Angiography; Migraine Disorders; Nicardipine; Phosphodiesterase Inhibitors; Stents; Stroke; Vasoconstrictor Agents; Vasodilator Agents; Vasospasm, Intracranial | 2012 |
Intravenous dihydroergotamine for inpatient management of refractory primary headaches.
Topics: Adult; Analgesics, Non-Narcotic; Cluster Headache; Dihydroergotamine; Disease Management; Drug Administration Schedule; Female; Follow-Up Studies; Headache Disorders, Primary; Humans; Injections, Intravenous; Inpatients; Male; Middle Aged; Migraine Disorders; Pain, Intractable; Treatment Outcome | 2011 |
Headache currents commentary.
Topics: Analgesics; Animals; Dihydroergotamine; Ergotamine; Headache; Humans; Methysergide; Migraine Disorders; Sumatriptan | 2012 |
Headache in three new cases of Harlequin syndrome with accompanying pharmacological comparison with migraine.
Topics: Adult; Aged; Autonomic Nervous System Diseases; Diagnosis, Differential; Dihydroergotamine; Ergotamine; Female; Flushing; Headache; Humans; Hypohidrosis; Middle Aged; Migraine Disorders; Nitroglycerin; Sumatriptan; Vasoconstrictor Agents; Vasodilator Agents | 2012 |
The antimigraine 5-HT 1B/1D receptor agonists, sumatriptan, zolmitriptan and dihydroergotamine, attenuate pain-related behaviour in a rat model of trigeminal neuropathic pain.
Topics: Animals; Dihydroergotamine; Disease Models, Animal; Male; Migraine Disorders; Oxazolidinones; Pain; Pain Threshold; Rats; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1B; Receptor, Serotonin, 5-HT1D; Receptors, Serotonin; Serotonin Receptor Agonists; Sumatriptan; Trigeminal Nerve Diseases; Tryptamines | 2002 |
Variations among emergency departments in the treatment of benign headache.
Topics: Adolescent; Adult; Aged; Algorithms; Analgesics, Non-Narcotic; Analgesics, Opioid; Antiemetics; Binomial Distribution; Cohort Studies; Confidence Intervals; Dihydroergotamine; Diphenhydramine; Drug Therapy, Combination; Emergency Service, Hospital; Female; Headache; Health Maintenance Organizations; Hospitals, Rural; Hospitals, University; Humans; Male; Meperidine; Middle Aged; Migraine Disorders; Practice Guidelines as Topic; Prochlorperazine; Retrospective Studies; Tension-Type Headache; United States | 2003 |
Dysphonia associated with carotidynia and migraine responding to dihydroergotamine.
Topics: Carotid Arteries; Dihydroergotamine; Female; Humans; Middle Aged; Migraine Disorders; Neck Pain; Recurrence; Voice Disorders | 2003 |
Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.
Topics: Amphetamines; Animals; Binding, Competitive; Cell Line; Cyclic GMP; Dihydroergotamine; Humans; Inositol Phosphates; Iodine Radioisotopes; Kinetics; Migraine Disorders; Radioligand Assay; Receptor, Serotonin, 5-HT2B; Receptor, Serotonin, 5-HT2C; Serotonin 5-HT2 Receptor Agonists; Serotonin Receptor Agonists; Time Factors; Treatment Outcome | 2003 |
[Ergotamine-caffeine and dihydroergotamine-caffeine in migraine therapy].
Topics: Caffeine; Dihydroergotamine; Drug Combinations; Ergot Alkaloids; Ergotamine; Humans; Migraine Disorders; Oxytocics | 1952 |
The action of ergotamine on the intracranial venous pressure and on the cerebral venous outflow of the dog.
Topics: Animals; Brain; Cerebral Veins; Cerebrovascular Circulation; Dihydroergotamine; Dogs; Ergot Alkaloids; Ergotamine; Hypertension; Intracranial Pressure; Migraine Disorders; Vasoconstriction; Vasoconstrictor Agents; Venous Pressure | 1957 |
Preventive treatment of migraine with dihydroergotamine.
Topics: Amides; Dihydroergotamine; Humans; Migraine Disorders | 1958 |
[Treatment of migraine patients with inhalation of dihydroergotamine].
Topics: Administration, Inhalation; Dihydroergotamine; Humans; Migraine Disorders | 1962 |
[Efficacy of dihydroergotamine in ophthalmic hemicrania and glaucoma].
Topics: Dihydroergotamine; Ergot Alkaloids; Eye; Glaucoma; Headache; Humans; Migraine Disorders | 1950 |
[Treatment of migraine by dihydroergotamine].
Topics: Dihydroergotamine; Ergonovine; Ergot Alkaloids; Humans; Migraine Disorders | 1950 |
Headaches that could spell trouble.
Topics: Dihydroergotamine; Headache; Humans; Migraine Disorders; Sumatriptan | 2004 |
Further experience with dihydroergotamine methanesulfonate in the treatment of migraine; with a note on the use of cafergone.
Topics: Claviceps; Dihydroergotamine; Ergonovine; Ergot Alkaloids; Humans; Migraine Disorders | 1949 |
Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache.
Topics: Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Antiemetics; Dihydroergotamine; Diphenhydramine; Drug Therapy, Combination; Female; Histamine H1 Antagonists; Humans; Injections, Intravenous; Male; Metoclopramide; Middle Aged; Migraine Disorders; Nausea | 2005 |
Evaluation of the anti-emetic potential of anti-migraine drugs to prevent resiniferatoxin-induced emesis in Suncus murinus (house musk shrew).
Topics: Animals; Antiemetics; Butanols; Capsaicin; Cyclooxygenase Inhibitors; Dihydroergotamine; Diphenhydramine; Diterpenes; Domperidone; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Humans; Indomethacin; Malates; Methysergide; Metoclopramide; Migraine Disorders; Ondansetron; Piperidines; Ruthenium Red; Scopolamine; Serotonin Antagonists; Serotonin Receptor Agonists; Shrews; Sumatriptan; Time Factors; Tropanes; Vomiting | 2005 |
Successful treatment of status migrainosus after electroconvulsive therapy with dihydroergotamine.
Topics: Dihydroergotamine; Electroconvulsive Therapy; Female; Humans; Middle Aged; Migraine Disorders; Vasoconstrictor Agents | 2005 |
Patient information regarding subcutaneous self-administration of dihydroergotamine (DHE).
Topics: Analgesics, Non-Narcotic; Dihydroergotamine; Humans; Injections, Subcutaneous; Migraine Disorders; Self Administration | 2007 |
Triptans: actions and reactions.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Analgesics, Non-Narcotic; Dihydroergotamine; Female; Herpes Simplex; Herpesvirus 2, Human; Humans; Migraine Disorders; Neuralgia, Postherpetic; Pyrrolidines; Serotonin Receptor Agonists; Skin; Sumatriptan; Tryptamines | 2008 |
Possible iatrogenic bilateral cerebral ischemic infarcts in a woman with vasculitis.
Topics: Adult; Analgesics, Non-Narcotic; Cerebral Angiography; Cerebral Infarction; Diffusion Magnetic Resonance Imaging; Dihydroergotamine; Female; Humans; Migraine Disorders; Vasculitis | 2008 |
[What is safe in the treatment of headache?].
Topics: Anti-Anxiety Agents; Benzodiazepines; Cerebrovascular Disorders; Cluster Headache; Delayed-Action Preparations; Dihydroergotamine; Dihydroergotoxine; Headache; Humans; Methysergide; Migraine Disorders; Vascular Headaches | 1981 |
Effects on arterial receptors of ergot derivatives used in migraine.
Topics: Animals; Cattle; Dihydroergotamine; Dogs; Dose-Response Relationship, Drug; Ergotamines; Humans; In Vitro Techniques; Migraine Disorders; Muscle, Smooth, Vascular; Norepinephrine; Phentolamine; Pizotyline; Receptors, Adrenergic, alpha; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Vasoconstrictor Agents; Vasomotor System | 1982 |
[Headache in children].
Topics: Brain Neoplasms; Child; Child, Preschool; Contusions; Dihydroergotamine; Ergotamine; Headache; Humans; Hypertension, Renal; Migraine Disorders; Prognosis; Propranolol; Vascular Headaches | 1984 |
Drug management of adult vascular headaches (migraine and cluster headache): Part I--Treatment of the acute attack.
Topics: Cluster Headache; Dihydroergotamine; Ergotamine; Humans; Metoclopramide; Migraine Disorders; Vascular Headaches | 1984 |
On the treatment of migraine. Pharmacokinetic-pharmacodynamic relationships for a programmed release formulation of dihydroergotamine administered orally in the human.
Topics: Administration, Oral; Adult; Biological Availability; Chemical Phenomena; Chemistry; Delayed-Action Preparations; Dihydroergotamine; Humans; Kinetics; Male; Migraine Disorders | 1983 |
Menstrual migraine: intermittent prophylaxis with a timed-release pharmacological formulation of dihydroergotamine.
Topics: Adult; Delayed-Action Preparations; Dihydroergotamine; Female; Humans; Menstruation; Migraine Disorders; Time Factors | 1983 |
Progress in migraine: treatment with dihydroergotamine-retard.
Topics: Delayed-Action Preparations; Dihydroergotamine; Female; Humans; Male; Migraine Disorders | 1983 |
DHE retard for prophylactic therapy of migraine: efficacy and tolerability.
Topics: Adolescent; Adult; Delayed-Action Preparations; Dihydroergotamine; Drug Tolerance; Female; Humans; Male; Middle Aged; Migraine Disorders | 1983 |
Clinical pharmacological aspects of dihydroergotamine timed release: activity on monoamine venospasm.
Topics: Adult; Delayed-Action Preparations; Dihydroergotamine; Female; Hand; Humans; Male; Middle Aged; Migraine Disorders; Norepinephrine; Serotonin; Spasm; Venous Pressure | 1983 |
Pharmacology of arteriovenous anastomoses.
Topics: Animals; Arteriovenous Anastomosis; Cats; Cerebrovascular Circulation; Dihydroergotamine; Ergotamine; Humans; Methylamines; Methysergide; Migraine Disorders; Sympathomimetics | 1982 |
Antimigraine drugs and cranial arteriovenous shunting in the cat.
Topics: Animals; Arteriovenous Shunt, Surgical; Blood Gas Analysis; Carotid Arteries; Cats; Cerebrovascular Circulation; Dihydroergotamine; Ergotamine; Migraine Disorders; Oxygen; Skull | 1980 |
[Need for gastric acidification in the treatment of abdominal migraine. Results of a multicenter study on the association of Séglor retard and Vagosérine].
Topics: Adult; Aged; Dihydroergotamine; Drug Combinations; Female; Glutamates; Humans; Male; Middle Aged; Migraine Disorders; Papain; Physostigmine | 1980 |
Management of migraine.
Topics: Analgesics; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders | 1981 |
[Complications in the treatment of migraine with ergotamine and its derivatives].
Topics: Adult; Dihydroergotamine; Ergotamine; Ergotism; Female; Humans; Ischemia; Leg; Migraine Disorders; Vasoconstrictor Agents | 1981 |
Dihydroergotamine nasal spray.
Topics: Administration, Intranasal; Bias; Controlled Clinical Trials as Topic; Dihydroergotamine; Humans; Migraine Disorders; Pain Measurement; Reproducibility of Results; Research Design | 1995 |
Drugs for migraine.
Topics: Adrenergic beta-Antagonists; Analgesics; Dihydroergotamine; Humans; Migraine Disorders; Sumatriptan | 1995 |
Practice parameter: appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus (summary statement). Report of the Quality Standards Subcommittee of the American Academy of Neurology.
Topics: Dihydroergotamine; Ergotamine; Humans; Migraine Disorders | 1995 |
Anti-migraine compounds fail to modulate the propagation of cortical spreading depression in the cat.
Topics: Analgesics; Animals; Aspirin; Cats; Cerebral Cortex; Clonazepam; Cortical Spreading Depression; Dihydroergotamine; Dizocilpine Maleate; Female; Halothane; Lidocaine; Metoprolol; Migraine Disorders; Receptors, N-Methyl-D-Aspartate; Regional Blood Flow; Ultrasonography, Doppler, Transcranial; Valproic Acid | 1994 |
Home administration of intramuscular DHE for the treatment of acute migraine headache.
Topics: Acute Disease; Adolescent; Adult; Dihydroergotamine; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Migraine Disorders; Self Administration | 1994 |
Recommendations for the emergency treatment of migraine headache.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Dexamethasone; Dihydroergotamine; Emergency Medical Services; Humans; Ketorolac; Migraine Disorders; Sumatriptan; Tolmetin | 1994 |
Office-based treatment of acute migraine with dihydroergotamine mesylate.
Topics: Acute Disease; Adolescent; Adult; Aged; Dihydroergotamine; Female; Humans; Injections, Intramuscular; Male; Middle Aged; Migraine Disorders; Office Visits | 1993 |
[Improper equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
Topics: Dihydroergotamine; Ergotamine; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan; Vasoconstrictor Agents | 1993 |
The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats.
Topics: Adolescent; Adult; Animals; Blood Vessels; Cats; Cerebrovascular Circulation; Dihydroergotamine; Female; Humans; Indoles; Laser-Doppler Flowmetry; Male; Middle Aged; Migraine Disorders; Neuropeptides; Sulfonamides; Sumatriptan; Trigeminal Ganglion; Vasoconstrictor Agents | 1993 |
[Unjustified equalization of sumatriptan with ergotamine and dihydroergotamine in the Drug Equivalency System].
Topics: Dihydroergotamine; Ergotamine; Humans; Indoles; Migraine Disorders; Serotonin Receptor Agonists; Sulfonamides; Sumatriptan; Therapeutic Equivalency; Vasoconstrictor Agents | 1993 |
Dihydroergotamine local reactions reduced by normal saline.
Topics: Adult; Dihydroergotamine; Female; Humans; Migraine Disorders; Sodium Chloride | 1993 |
Coexistence of migraine and idiopathic intracranial hypertension without papilledema.
Topics: Acetazolamide; Adolescent; Adult; Dihydroergotamine; Diuretics; Ergotamine; Female; Follow-Up Studies; Furosemide; Headache; Humans; Intracranial Pressure; Male; Middle Aged; Migraine Disorders; Obesity; Papilledema; Pseudotumor Cerebri; Sumatriptan | 1996 |
Onset of neurologic deficits after treatment with dihydroergotamine in a patient with sagittal sinus thrombosis.
Topics: Adult; Angiography; Dihydroergotamine; Fatal Outcome; Female; Humans; Intracranial Pressure; Migraine Disorders; Nervous System Diseases; Sinus Thrombosis, Intracranial; Tomography, X-Ray Computed; Vasoconstrictor Agents | 1996 |
Serotonin syndrome complicating migraine pharmacotherapy.
Topics: Adult; Autonomic Nervous System Diseases; Dihydroergotamine; Drug Synergism; Female; Gastrointestinal Diseases; Humans; Injections, Intravenous; Injections, Subcutaneous; Lithium; Mental Disorders; Migraine Disorders; Movement Disorders; Serotonin Receptor Agonists; Sumatriptan; Syndrome | 1996 |
Effect of antimigraine drugs on dural blood flows and resistances and the responses to trigeminal stimulation.
Topics: Animals; Blood Pressure; Carotid Arteries; Cats; Dihydroergotamine; Dose-Response Relationship, Drug; Heart Rate; Injections, Intravenous; Meningeal Arteries; Migraine Disorders; Regional Blood Flow; Sumatriptan; Trigeminal Ganglion; Vascular Resistance; Vasoconstrictor Agents | 1996 |
Subcutaneous dihydroergotamine vs subcutaneous sumatriptan.
Topics: Dihydroergotamine; Humans; Injections, Subcutaneous; Migraine Disorders; Sumatriptan | 1996 |
Effectiveness of subcutaneous dihydroergotamine by home injection for migraine.
Topics: Adult; Analgesics, Non-Narcotic; Dihydroergotamine; Female; Home Nursing; Humans; Injections, Subcutaneous; Male; Middle Aged; Migraine Disorders; Retrospective Studies; Self Administration | 1996 |
Appropriate use of ergotamine tartrate and dihydroergotamine in the treatment of migraine: current perspectives.
Topics: Analgesics, Non-Narcotic; Contraindications; Dihydroergotamine; Ergotamine; Humans; Migraine Disorders; Practice Guidelines as Topic | 1997 |
[The treatment of migraine].
Topics: Adrenergic beta-Antagonists; Amitriptyline; Calcium Channel Blockers; Dihydroergotamine; Ergotamine; Flunarizine; Humans; Methysergide; Migraine Disorders; Nicardipine; Nimodipine; Serotonin Antagonists; Serotonin Receptor Agonists; Sumatriptan; Vasoconstrictor Agents | 1997 |
Agonist activity of antimigraine drugs at recombinant human 5-HT1A receptors: potential implications for prophylactic and acute therapy.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Benzopyrans; Binding, Competitive; Cell Membrane; Cricetinae; Dihydroergotamine; Guanosine 5'-O-(3-Thiotriphosphate); Guinea Pigs; Humans; In Vitro Techniques; Indoles; Lisuride; Methysergide; Migraine Disorders; Piperazines; Piperidines; Pizotyline; Propranolol; Propylamines; Protein Binding; Pyridines; Pyrimidines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Recombinant Proteins; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Sumatriptan; Tryptamines | 1997 |
[Critical evaluation of "guidelines"].
Topics: Adult; Dihydroergotamine; Female; Humans; Migraine Disorders; Practice Guidelines as Topic; Quality Assurance, Health Care; Sumatriptan; Switzerland | 1998 |
Coronary side-effect potential of current and prospective antimigraine drugs.
Topics: Adolescent; Adult; Aged; Angina Pectoris; Child; Coronary Vessels; Dihydroergotamine; Ergotamine; Female; Humans; In Vitro Techniques; Indoles; Male; Methysergide; Middle Aged; Migraine Disorders; Piperidines; Sulfonamides; Sumatriptan; Triazoles; Tryptamines; Vasoconstrictor Agents | 1998 |
[Bilateral ischemic optic neuropathy secondary to acute ergotism].
Topics: Adult; Anti-Bacterial Agents; Dihydroergotamine; Ergotamine; Ergotism; Humans; Hypertension; Macrolides; Male; Migraine Disorders; Optic Neuropathy, Ischemic; Vasoconstrictor Agents; Visual Acuity | 1998 |
New "triptans" and other drugs for migraine.
Topics: Adrenergic beta-Antagonists; Amitriptyline; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents, Tricyclic; Calcium Channel Blockers; Dihydroergotamine; Drug Interactions; Ergotamine; Humans; Indoles; Methysergide; Migraine Disorders; Naproxen; Oxazoles; Oxazolidinones; Piperidines; Propranolol; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sumatriptan; Time Factors; Timolol; Triazoles; Tryptamines; Valproic Acid; Vasoconstrictor Agents | 1998 |
[Finger tip necroses after dihydroergotamine medication in limited systemic scleroderma].
Topics: Aged; Contraindications; Dihydroergotamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fingers; Humans; Migraine Disorders; Necrosis; Raynaud Disease; Risk Factors; Scleroderma, Systemic | 1998 |
[Treatment of acute attacks of migraine by dihydergot: nasal aerosols].
Topics: Acute Disease; Adult; Aerosols; Analgesics, Non-Narcotic; Dihydroergotamine; Female; Humans; Male; Middle Aged; Migraine Disorders; Time Factors | 1999 |
[Transformed migraine--chronic daily headache].
Topics: Adult; Analgesics, Non-Narcotic; Chronic Disease; Dihydroergotamine; Female; Headache; Humans; Injections, Intravenous; Male; Middle Aged; Migraine Disorders; Patient Satisfaction; Terminology as Topic; Treatment Outcome; Vasoconstrictor Agents | 1999 |
Transient global amnesia, migraine, thalamic infarct, dihydroergotamine, and sumatriptan.
Topics: Amnesia, Transient Global; Brain Infarction; Dihydroergotamine; Female; Humans; Injections, Subcutaneous; Middle Aged; Migraine Disorders; Sumatriptan; Vasoconstrictor Agents | 2000 |
[Migraine treatment].
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Antiemetics; Aspirin; Dihydroergotamine; Drug Therapy, Combination; Ergotamine; Humans; Migraine Disorders; Serotonin Receptor Agonists; Severity of Illness Index; Vasoconstrictor Agents | 2000 |
Sumatriptan nasal spray in the acute treatment of migraine: a review of clinical studies.
Topics: Dihydroergotamine; Humans; Migraine Disorders; Nebulizers and Vaporizers; Sumatriptan; Vasoconstrictor Agents | 2000 |
[Effect of migraine medications on monocyte chemotaxis] .
Topics: Adult; Analgesics; Aspirin; Chemotaxis, Leukocyte; Dihydroergotamine; Humans; Immune Tolerance; Male; Metoclopramide; Metoprolol; Migraine Disorders; Propranolol; Sumatriptan | 2000 |
[Pharmaco-epidemiological study on the prophylactic treatment of migraine. National inquiry on attitude to prescription practices by primary care physicians and neurologists in Franceø].
Topics: Adrenergic beta-Antagonists; Dihydroergotamine; Family Practice; France; Humans; Migraine Disorders; Neurology; Physicians, Family; Surveys and Questionnaires; Telephone | 2000 |
Sumatriptin vs dihydroergotamine: patient preference.
Topics: Administration, Inhalation; Analgesics, Non-Narcotic; Dihydroergotamine; Humans; Migraine Disorders; Patient Satisfaction; Serotonin Receptor Agonists; Sumatriptan | 2001 |
Status migrainosus in children and adolescents.
Topics: Adolescent; Child; Diagnosis, Differential; Dihydroergotamine; Drug Therapy, Combination; Female; Follow-Up Studies; Genetic Predisposition to Disease; Humans; Male; Meperidine; Methylprednisolone; Migraine Disorders; Prednisolone; Sumatriptan | 2001 |
Sumatriptan by injection.
Topics: Clinical Trials as Topic; Dihydroergotamine; Dose-Response Relationship, Drug; Humans; Injections, Subcutaneous; Migraine Disorders; Sumatriptan; Treatment Outcome | 2001 |
[Migraine and facial pain].
Topics: Adult; Analgesics; Analgesics, Non-Narcotic; Carbamazepine; Child; Diagnosis, Differential; Dihydroergotamine; Facial Pain; Female; Humans; Male; Methysergide; Middle Aged; Migraine Disorders; Oxygen Inhalation Therapy; Psychotherapy; Serotonin Antagonists; Sumatriptan; Time Factors; Trigeminal Neuralgia; Vasoconstrictor Agents | 2001 |
[Migraine: a disease, not a symptom].
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analgesics; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Atenolol; Diagnosis, Differential; Dihydroergotamine; Flunarizine; GABA Agents; Humans; Indoramin; Methysergide; Migraine Disorders; Oxazolidinones; Serotonin Antagonists; Serotonin Receptor Agonists; Tryptamines; Valproic Acid; Vasoconstrictor Agents; Vasodilator Agents | 2002 |
[Stellate ganglion block under EEG control in the treatment of complicated cervical migraine (author's transl)].
Topics: Adult; Autonomic Nerve Block; Cinnarizine; Craniocerebral Trauma; Dihydroergotamine; Electroencephalography; Humans; Male; Migraine Disorders; Procaine; Pyrithioxin; Stellate Ganglion | 1975 |
[Mechanism of action of drugs currently used in the prevention of migraine].
Topics: Adrenergic beta-Antagonists; Catecholamines; Cerebrovascular Circulation; Chemical Phenomena; Chemistry; Clonidine; Dihydroergotamine; Ergotamine; Histamine Release; Humans; Kinins; Methysergide; Migraine Disorders; Pizotyline; Serotonin Antagonists | 1976 |
[Drug therapy of migraine and cluster headache].
Topics: Analgesics; Barbiturates; Caffeine; Dihydroergotamine; Drug Synergism; Ergot Alkaloids; Headache; Histamine H1 Antagonists; Humans; Methysergide; Migraine Disorders; Vascular Headaches | 1975 |
[Drug therapy for headache: (author's transl)].
Topics: Analgesics; Anti-Inflammatory Agents; Antidepressive Agents; Clonidine; Dihydroergotamine; Ergotamine; Headache; Humans; Migraine Disorders; Neuralgia; Pizotyline; Sleep; Substance-Related Disorders; Tranquilizing Agents | 1977 |
Cluster headache: relation to and comparison with migraine.
Topics: Cluster Headache; Diagnosis, Differential; Dihydroergotamine; Ergotamine; Female; Humans; Male; Methysergide; Migraine Disorders; Prednisone; Vascular Headaches | 1979 |
Potentiation and antagonism of serotonin effects on intracranial and extracranial vessels. Possible implications in migraine.
Topics: Animals; Arteries; Cats; Cerebral Arteries; Cyproheptadine; Dihydroergotamine; Drug Synergism; Ergotamine; Humans; In Vitro Techniques; Methysergide; Migraine Disorders; Pizotyline; Serotonin; Serotonin Antagonists; Vasoconstriction; Vasomotor System | 1978 |
Migraine. Prophylactic drugs.
Topics: Anticonvulsants; Clonidine; Cyproheptadine; Dihydroergotamine; Humans; Methysergide; Migraine Disorders; Pizotyline; Propranolol; Tranquilizing Agents | 1977 |
[The long term use of dihydroergotamine (DHE-45) in migraine treatment (author's transl)].
Topics: Adult; Dihydroergotamine; Female; Hemodynamics; Humans; Male; Middle Aged; Migraine Disorders; Time Factors | 1978 |
[Letter: Coronary spasm following ergotamine medication].
Topics: Adult; Angina Pectoris; Coronary Disease; Coronary Vessels; Dihydroergotamine; Ergotamine; Headache; Humans; Male; Migraine Disorders | 1975 |
[Iatrogenic ergotism].
Topics: Adult; Dihydroergotamine; Ergotamines; Ergotism; Female; Humans; Migraine Disorders | 1977 |
Bilateral retinal hemorrhages and disk edema in migraine.
Topics: Adult; Belladonna Alkaloids; Child; Cyproheptadine; Dihydroergotamine; Female; Fluorescein Angiography; Humans; Male; Migraine Disorders; Papilledema; Radiography; Retinal Hemorrhage; Skull; Vomiting | 1977 |
[The use of drugs in migraine].
Topics: Acetaminophen; Antiemetics; Aspirin; Clonidine; Dihydroergotamine; Ergotamine; Humans; Hypnotics and Sedatives; Methysergide; Migraine Disorders; Tranquilizing Agents | 1976 |
Letter: Oral dihydroergotamine in management of cluster headache.
Topics: Administration, Oral; Dihydroergotamine; Ergotamines; Female; Humans; Middle Aged; Migraine Disorders | 1976 |
Lack of effect of the antimigraine drugs, sumatriptan, ergotamine and dihydroergotamine on arteriovenous anastomotic shunting in the dura mater of the pig.
Topics: Animals; Arteriovenous Anastomosis; Dihydroergotamine; Dura Mater; Ergotamine; Hemodynamics; Indoles; Microspheres; Migraine Disorders; Regional Blood Flow; Sulfonamides; Sumatriptan; Swine; Vasoconstrictor Agents | 1992 |
5-Hydroxtryptamine1D receptor agonism predicts antimigraine efficacy.
Topics: Adenylyl Cyclase Inhibitors; Amitriptyline; Animals; Cattle; Caudate Nucleus; Dihydroergotamine; Ergotamine; Indoles; Kinetics; Methysergide; Migraine Disorders; Radioligand Assay; Receptors, Serotonin; Serotonin; Sulfonamides; Sumatriptan; Vasoconstrictor Agents; Verapamil | 1991 |
Evidence for 5-HT1B/1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine.
Topics: Animals; Blood Proteins; Calcitonin Gene-Related Peptide; Capillary Permeability; Cerebrovascular Circulation; Cranial Sinuses; Dihydroergotamine; Electric Stimulation; Indoles; Male; Mast Cells; Migraine Disorders; Rats; Rats, Inbred Strains; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Sulfonamides; Sumatriptan; Trigeminal Ganglion; Vasoconstrictor Agents | 1991 |
The hospital management of severe migrainous headache.
Topics: Adolescent; Adult; Aged; Child; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Indoles; Lidocaine; Male; Middle Aged; Migraine Disorders; Retrospective Studies; Sulfonamides; Sumatriptan | 1991 |
A case of portal thrombosis arisen after treatment with dihydroergotamine.
Topics: Adult; Dihydroergotamine; Female; Humans; Migraine Disorders; Portal Vein; Thrombosis; Time Factors | 1991 |
Dihydroergotamine suppositories in a headache clinic.
Topics: Dihydroergotamine; Headache; Humans; Migraine Disorders; Suppositories | 1991 |
The antimigraine drugs ergotamine and dihydroergotamine are potent 5-HT1C receptor agonists in piglet choroid plexus.
Topics: Animals; Binding, Competitive; Choroid Plexus; Dihydroergotamine; Ergolines; Ergotamine; In Vitro Techniques; Inositol Phosphates; Migraine Disorders; Piperazines; Receptors, Serotonin; Serotonin; Swine; Thermodynamics | 1991 |
Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Dihydroergotamine; Drug Therapy, Combination; Humans; Ketorolac; Metoclopramide; Migraine Disorders; Tolmetin | 1991 |
Localization of 3H-dihydroergotamine-binding sites in the cat central nervous system: relevance to migraine.
Topics: Animals; Autoradiography; Binding Sites; Cats; Central Nervous System; Dihydroergotamine; Female; Male; Migraine Disorders | 1991 |
Claudication: an unusual side effect of DHE administration.
Topics: Adult; Dihydroergotamine; Female; Humans; Intermittent Claudication; Middle Aged; Migraine Disorders; Pulse; Vascular Diseases | 1991 |
Treatment of status migrainosus: the American experience.
Topics: Acute Disease; Algorithms; Analgesics; Contraindications; Dihydroergotamine; Drug Administration Schedule; Drug Tolerance; Humans; Migraine Disorders; Substance-Related Disorders; United States | 1990 |
Abortive versus prophylactic treatment of migraine--a reappraisal.
Topics: Dihydroergotamine; Humans; Migraine Disorders; Propranolol | 1990 |
Haloperidol and lorazepam for the treatment of nausea and vomiting associated with the treatment of intractable migraine headaches.
Topics: Adult; Dihydroergotamine; Female; Haloperidol; Humans; Lorazepam; Migraine Disorders; Nausea; Vomiting | 1989 |
[Beta receptor blockers in migraine].
Topics: Adrenergic beta-Antagonists; Anti-Anxiety Agents; Cinnarizine; Dihydroergotamine; Dose-Response Relationship, Drug; Flunarizine; Humans; Hypotension; Migraine Disorders; Time Factors | 1985 |
[Antimigrainous agents. General considerations and treatment of the crisis].
Topics: Acupuncture Therapy; Amitriptyline; Analgesics; Anti-Anxiety Agents; Anti-Inflammatory Agents; Antiemetics; Caffeine; Dihydroergotamine; Ergotamine; Ergotamines; Humans; Migraine Disorders | 1986 |
[Antimigrainous agents used in maintenance treatment].
Topics: Adrenergic beta-Antagonists; Amitriptyline; Aspirin; Benzoxepins; Calcium Channel Blockers; Cinnarizine; Clonidine; Dihydroergotamine; Flunarizine; Humans; Methysergide; Migraine Disorders; Pizotyline; Propranolol | 1986 |
[Ergotismus as a consequence of migraine prevention].
Topics: Adult; Chronic Disease; Dihydroergotamine; Ergotism; Female; Femoral Artery; Heparin; Humans; Ischemia; Leg; Migraine Disorders; Popliteal Artery; Thromboembolism | 1987 |
IV dihydroergotamine therapy for migraine treatment.
Topics: Dihydroergotamine; Emergency Medicine; Humans; Injections, Intravenous; Migraine Disorders | 1988 |
[Treatment of migraine attacks in children with dihydroergotamine Spofa and lysenyl].
Topics: Adolescent; Child; Dihydroergotamine; Electroencephalography; Ergolines; Female; Humans; Lisuride; Male; Migraine Disorders | 1986 |
Emergency treatment of intractable migraine.
Topics: Adult; Dexamethasone; Dihydroergotamine; Drug Therapy, Combination; Female; Humans; Male; Meperidine; Migraine Disorders; Pain, Intractable; Promethazine | 1986 |
Ergotamine-induced colitis.
Topics: Colitis, Ulcerative; Dihydroergotamine; Female; Humans; Middle Aged; Migraine Disorders; Proctitis; Sigmoidoscopy; Suppositories; Time Factors | 1985 |
[Ergotamine-induced disorders of the peripheral blood circulation--a case report].
Topics: Adult; Dihydroergotamine; Female; Humans; Ischemia; Leg; Migraine Disorders | 1985 |
The management of migraine.
Topics: Clonidine; Diet; Dihydroergotamine; Female; Humans; Male; Methysergide; Migraine Disorders; Pizotyline; Propranolol | 1985 |
[Retroperitoneal fibrosis and ergot derivatives. Ophthalmological adverse effects].
Topics: Dihydroergotamine; Ergotamines; Humans; Male; Middle Aged; Migraine Disorders; Retroperitoneal Fibrosis | 1974 |